You can accuse me of causing ''years of damage,'' but all I've done is point out what the data and trial history actually show. The DCVax-L trial and its data are riddled with problems. These aren't ''half-truths'' - they are facts acknowledged by multiple independent experts, including Prof. Stupp, one of the most respected authorities in glioblastoma.
Even if regulatory approval ever comes, it won't erase all the flaws in the trial or prove that DCVax-L is effective. Regulators sometimes approve treatments on (very) limited evidence, often due to unmet need or other considerations. That possibility - however slim - doesn't rewrite history or change the data.